product summary
Loading...
company name :
Bioss
product type :
antibody
product name :
NARC1 Polyclonal Antibody
catalog :
bs-6060R
quantity :
100 ul
price :
289.5 USD
clonality :
polyclonal
host :
rabbit
conjugate :
nonconjugated
reactivity :
human, mouse, rat
application :
western blot, immunocytochemistry, immunohistochemistry - paraffin section
more info or order :
Bioss product webpage
citations: 1
Published Application/Species/Sample/DilutionReference
  • immunohistochemistry - paraffin section; rat; fig 4
Jia L, Song N, Yang G, Ma Y, Li X, Lu R, et al. Effects of Tanshinone IIA on the modulation of miR‑33a and the SREBP‑2/Pcsk9 signaling pathway in hyperlipidemic rats. Mol Med Rep. 2016;13:4627-35 pubmed publisher
product information
sku :
bs-6060R
name :
NARC1 Polyclonal Antibody
category :
Primary Antibody
conjugation :
Unconjugated
host :
Rabbit
target protein :
NARC1
modification :
Unmodified
clonality :
Polyclonal
isotype :
IgG
concentration :
1ug/ul
public immunogen range :
235-285/692
subcellular locations :
Cytoplasm, Secreted, Lysosome
source :
KLH conjugated synthetic peptide derived from human PCSK9/NARC1
gene id link :
Entrez Gene: 255738
swiss prot :
Q8NBP7
swiss prot link :
Swiss Prot: Q8NBP7
applications :
WB, IHC-P, IF(IHC-P)
applications with dilutions :
WB(1:100-1000), IHC-P(1:100-500), IF(IHC-P)(1:50-200)
cross reactive species :
Human, Mouse, Rat
size :
100 ul
price :
289.5 USD
background :
Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments (PubMed:18039658). Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed:18799458, PubMed:17461796, PubMed:18197702, PubMed:22074827). Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway (PubMed:18660751). Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.
purification :
Purified by Protein A.
storage :
Aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Store at -20°C for 12 months.
synonyms :
FH3; PC9; NARC1; LDLCQ1; NARC-1; HCHOLA3; Proprotein convertase subtilisin/kexin type 9; Neural apoptosis-regulated convertase 1; Proprotein convertase 9; Subtilisin/kexin-like protease PC9; PCSK9; PSEC0052
lead time :
3 to 5 business days.
more info or order :
Bioss product webpage
company information
Bioss
500 West Cummings Park
Suite 6500
Woburn, MA 01801
info@biossusa.com
biossusa.com
800-501-7654
headquarters: USA
Bioss Inc is a leading antibody developer and manufacturer with state of the art technologies. We have developed over 11,000 antigens/primary antibodies and more than 130,000 derived products including fluorochrome conjugated antibodies. In addition to reliable loading control and tag antibodies, our catalog includes over 1000 specific antibodies recognizing proteins with phosphorylation, acetylation, or methylation modifications. Our company promises fast delivery with strong, top quality scientific support. Bioss Inc is located in the greater Boston area of Massachusetts, the center of the world's largest and fastest growing biotech community.